Novogen (KZIA) Competitors $7.18 +0.02 (+0.28%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$7.23 +0.05 (+0.70%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. RNTX, CVKD, KZR, LPTX, QTTB, ENLV, XCUR, PASG, MTVA, and PRPHShould you be buying Novogen stock or one of its competitors? The main competitors of Novogen include Rein Therapeutics (RNTX), Cadrenal Therapeutics (CVKD), Kezar Life Sciences (KZR), Leap Therapeutics (LPTX), Q32 Bio (QTTB), Enlivex Therapeutics (ENLV), Exicure (XCUR), Passage Bio (PASG), MetaVia (MTVA), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Novogen vs. Its Competitors Rein Therapeutics Cadrenal Therapeutics Kezar Life Sciences Leap Therapeutics Q32 Bio Enlivex Therapeutics Exicure Passage Bio MetaVia ProPhase Labs Rein Therapeutics (NASDAQ:RNTX) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Which has higher earnings and valuation, RNTX or KZIA? Novogen has higher revenue and earnings than Rein Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.69-0.51Novogen$1.51M4.80-$17.56MN/AN/A Which has more risk and volatility, RNTX or KZIA? Rein Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Novogen has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Do analysts recommend RNTX or KZIA? Rein Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 629.93%. Novogen has a consensus price target of $16.50, suggesting a potential upside of 129.81%. Given Rein Therapeutics' higher probable upside, equities research analysts clearly believe Rein Therapeutics is more favorable than Novogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Novogen 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media prefer RNTX or KZIA? In the previous week, Novogen had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 5 mentions for Novogen and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 0.63 beat Novogen's score of 0.50 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in RNTX or KZIA? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is RNTX or KZIA more profitable? Novogen's return on equity of 0.00% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -141.11% -33.83% Novogen N/A N/A N/A SummaryNovogen beats Rein Therapeutics on 8 of the 12 factors compared between the two stocks. Get Novogen News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricNovogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.21M$3.36B$6.15B$10.64BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A21.3485.9927.64Price / Sales4.80488.26628.97141.97Price / CashN/A47.1938.3262.20Price / Book-0.7310.4312.956.79Net Income-$17.56M-$52.40M$3.30B$275.88M7 Day Performance9.45%4.97%3.69%1.84%1 Month Performance-12.97%17.02%10.68%8.84%1 Year Performance-64.37%34.38%83.35%36.10% Novogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIANovogen3.2206 of 5 stars$7.18+0.3%$16.50+129.8%-63.7%$7.21M$1.51M0.0012Analyst ForecastRNTXRein Therapeutics3.1548 of 5 stars$1.24+4.3%$10.00+705.9%N/A$28.93MN/A-0.469News CoveragePositive NewsAnalyst ForecastGap UpCVKDCadrenal Therapeutics2.606 of 5 stars$13.72+1.4%$32.00+133.2%+18.7%$28.13MN/A-1.554Analyst ForecastKZRKezar Life Sciences3.9374 of 5 stars$3.76-4.3%$9.00+139.4%-49.1%$27.54MN/A-0.3960Positive NewsAnalyst ForecastLPTXLeap Therapeutics2.5866 of 5 stars$0.66-13.1%$3.38+408.3%-70.9%$27.52MN/A-0.4240News CoverageAnalyst ForecastQTTBQ32 Bio3.0242 of 5 stars$2.24+3.0%$12.17+444.4%-93.2%$27.51M$1.16M-0.5239News CoverageGap UpENLVEnlivex Therapeutics2.8605 of 5 stars$1.13-1.3%$10.00+785.0%-23.7%$27.45MN/A-1.9570Analyst ForecastXCURExicure1.6602 of 5 stars$4.27-0.1%N/A+135.7%$26.96M$500K-1.1050Analyst ForecastGap DownPASGPassage Bio3.6509 of 5 stars$8.06+1.6%$75.67+838.8%-23.8%$25.62MN/A-0.44130Analyst ForecastMTVAMetaVia3.032 of 5 stars$1.05-3.2%$7.50+617.7%N/A$25.29MN/A0.008Analyst ForecastPRPHProPhase Labs0.3599 of 5 stars$0.61+2.2%N/A-77.7%$25.26M$6.77M-0.48130Analyst ForecastGap Up Related Companies and Tools Related Companies RNTX Alternatives CVKD Alternatives KZR Alternatives LPTX Alternatives QTTB Alternatives ENLV Alternatives XCUR Alternatives PASG Alternatives MTVA Alternatives PRPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredTesla’s $30 trillion pivotElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
